On Jan 09, major Wall Street analysts update their ratings for $Jasper Therapeutics (JSPR.US)$, with price targets ranging from $40 to $80.
BMO Capital analyst Etzer Darout maintains with a buy rating, and maintains the target price at $63.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $80.
Stifel analyst Benjamin Burnett maintains with a buy rating, and maintains the target price at $80.
BTIG analyst Justin Zelin maintains with a buy rating, and adjusts the target price from $90 to $64.
RBC Capital analyst Gregory Renza maintains with a buy rating, and adjusts the target price from $68 to $48.
Furthermore, according to the comprehensive report, the opinions of $Jasper Therapeutics (JSPR.US)$'s main analysts recently are as follows:
The sharp decline in Jasper Therapeutics' stock following initial data from BEACON highlights the current market's low tolerance for uncertainties within biotech sectors. While the data could have been stronger, the response seems excessive given the positive efficacy signals at 240mg and preliminary safety profiles. Better understanding of briquilimab's advantages and risks at future doses could potentially recalibrate the stock's valuation. The assessment of briquilimab's role in treating chronic spontaneous urticaria is still developing.
Following the recent presentation of data from the Phase 1b/2a BEACON study in chronic spontaneous urticaria, it has been noted that briquilimab proves active and efficacious in treating the condition, demonstrating a favorable early safety profile. Despite these positive findings, the stock has significantly declined. This is attributed to perceptions that briquilimab's market differentiation compared to competing treatments like Celldex's barzolvolimab is less significant. Future potential updates that could impact the stock include additional BEACON study data and preliminary asthma treatment data expected later this year.
Here are the latest investment ratings and price targets for $Jasper Therapeutics (JSPR.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间1月9日，多家华尔街大行更新了$Jasper Therapeutics (JSPR.US)$的评级，目标价介于40美元至80美元。
BMO资本市场分析师Etzer Darout维持买入评级，维持目标价63美元。
奥本海默控股分析师Jay Olson维持买入评级，维持目标价80美元。
斯迪富分析师Benjamin Burnett维持买入评级，维持目标价80美元。
BTIG分析师Justin Zelin维持买入评级，并将目标价从90美元下调至64美元。
加皇资本市场分析师Gregory Renza维持买入评级，并将目标价从68美元下调至48美元。
此外，综合报道，$Jasper Therapeutics (JSPR.US)$近期主要分析师观点如下：
雅斯珀治疗公司的股票因BEACON初步数据而急剧下降，这凸显了当前市场对生物技术行业不确定性的低容忍度。尽管数据本可以更强，但考虑到240mg的积极疗效信号和初步安全性资料，反应似乎过于激烈。更好地理解briquilimab在未来剂量中的优势和风险可能会重新调整股票的估值。briquilimab在治疗慢性自发性荨麻疹中的作用评估仍在发展中。
在近期慢性自发性荨麻疹的1b/2a期BEACON研究数据发布后，已注意到briquilimab在治疗该控件中活跃且有效，显示出良好的早期安全性资料。尽管这些积极的发现，股票却显著下跌。这归因于对briquilimab与竞争治疗（如Celldex的barzolvolimab）相比，其市场差异化程度的认知不足。未来可能影响股票的更新包括BEACON研究的附加数据以及预计在今年晚些时候发布的初步哮喘治疗数据。
以下为今日7位分析师对$Jasper Therapeutics (JSPR.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
